Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study

Catherina X Pan; Daniel Y Kim; Charles B Lau; William C Lau; Rachael Rowley; Ruhi Kanwar; Nicole R LeBoeuf; Vinod E Nambudiri

doi:10.1093/bjd/ljad271

Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study

Br J Dermatol. 2023 Oct 25;189(5):637-640. doi: 10.1093/bjd/ljad271.

Authors

Catherina X Pan^{1

2}, Daniel Y Kim^{1

2}, Charles B Lau^{2

3}, William C Lau^{2

4}, Rachael Rowley², Ruhi Kanwar^{1

2}, Nicole R LeBoeuf^{1

2

5}, Vinod E Nambudiri^{1

2

5}

Affiliations

¹ Harvard Medical School, Boston, MA, USA.
² Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
³ Boston University, Boston, MA, USA.
⁴ Boston University School of Medicine, Boston, MA, USA.
⁵ Dana-Farber Cancer Institute, Center for Cutaneous Oncology, MA, USA.

PMID: 37503686
DOI: 10.1093/bjd/ljad271

No abstract available

MeSH terms

Humans
Immune Checkpoint Inhibitors* / adverse effects
Ipilimumab / adverse effects
Melanoma*
Retrospective Studies

Substances

Immune Checkpoint Inhibitors
Ipilimumab

Grants and funding

Officde of Scholarly Engagement, Harvard Medical School